

Buy EUR 50.00 (EUR 76.00) Price EUR 14.75 Upside 239.0 %	Value Indicators: EUR SotP: 50.00	Warburg Risk Score: 2.1 Balance Sheet Score: 3.3 Market Liquidity Score: 1.0	Description: Brockhaus invests into high tech German Mittelstand companies
	Market Snapshot: EUR m Market cap: 154.1 No. of shares (m): 10.4 EV: 337.4 Freefloat MC: 119.6 Ø Trad. Vol. (30d): 94.58 th	Shareholders: Freefloat 77.60 % Marco Brockhaus 21.40 % DWS Investment 6.90 % Treasury shares 4.60 %	Key Figures (WRe): 2024e Beta: 1.7 Price / Book: 0.7 x Equity Ratio: 43 % Net Fin. Debt / EBITDA: 1.0 x Net Debt / EBITDA: 1.0 x

Bikeleasing introduces fee system for retailers

Brockhaus reported preliminary FY 24 figures and Q1 25, which were quite weak. In the Bikeleasing business, the number of leases facilitated dropped to double-digit negative rates while, at the same time, costs continued to rise on the implementation and roll-out of Probonio and Bike2Future. On top came discounts in the bike market, which were confirmed by the recent ZIV reporting, which cited a drop of 10% on average in the price of e-bikes in FY 24.


Looking at the details of the Q1 report, gross profit at Bikeleasing was again above EUR 800 per leased bike, which is a healthy level and means that the business model remains sound and profitable, once lease volumes come back. ZIV reported about 10% growth in bike sales in Q1 25, which were often discounted in clearing sales in order to lower inventories in our view. While the market growth slowed in April and May, leases at Bikeleasing picked up, driven, in our view, by lower discounts, which makes leasing more attractive. Starting in Q1 with -20% lower volumes, the first weeks in May were up by 6%. For FY 25, Brockhaus is expecting a positive growth rate for the full year.

Now, Bikeleasing has announced that it will introduce a fee and reward system for its connected retailers starting August 1. Bikeleasing was the last leasing company not charging retailers a fee. Now it is introducing 6%, limited to EUR 300 per bike (which translates into a max selling price of EUR 6,000 per bike). The fee can be regained if the bike retailer generates a new lease customer and can even be turned into commission of 3% if the retailer is very successful (>20 bikes with a new lease customer). We estimate that the 6% is effectively reduced by the claw-backs and commission to a level around 4.5% across all leased bikes. Yet this a powerful tool as it would have added around EUR 20m on an annual basis to the EUR 68m EBITDA that Bikeleasing showed in the preliminary results for FY 24.

Updating our model, we want to remain cautious on FY 25 lease figures and assume a flattish volume, which is a cut of roughly 30% to our last estimate. We also assume higher cost for the Probonio roll-out and a slower penetration of Bikeleasing customers. For FY 26, we assume a normalization of the bike market and a return to growth rates. Versus FY 23, we estimate the number of leased bikes will rise by 20%, which we think is conservative given that employees attached have, by now, already grown by this amount.

The postponement of the full audit caused by the early booking of revenues at IHSE and the weak Q1 drove down the share price. The trough in the bike market should have been found and the introduction of fee systems is to bring back growth to EBITDA and cash flow. This should bring back confidence to the stock over time. We keep our Buy rating. The PT drops from EUR 76 to EUR 50 but still implies significant upside.

Changes in Estimates:				Comment on Changes:			
FY End: 31.12. in EUR m	2024e (old)	+ / -	2025e (old)	+ / -	2026e (old)	+ / -	
Sales	228.6	-10.3 %	276.0	-21.0 %	322.8	-25.9 %	■ We estimate 143k leased bikes for FY 25 after 139k in FY 24. For FY 26, we assume an increase to 178k bikes.
EBITDA adj.	85.0	-22.4 %	113.6	-35.2 %	136.4	-19.1 %	■ For IHSE, we assume 5% sales growth, which is fully supported by the EUR 2.2m shift from FY 24 to FY 25.
Net income	20.7	-72.6 %	41.2	-44.8 %	50.8	-25.9 %	




Rel. Performance vs CDAX:	
1 month:	3.1 %
6 months:	-53.7 %
Year to date:	-51.8 %
Trailing 12 months:	-74.9 %

Company events:	
14.08.25	Q2
14.11.25	Q3


FY End: 31.12. in EUR m	CAGR (23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
Sales (pro forma)	8.6 %	51.6	126.5	145.3	186.7	205.0	218.2	239.1
Sales yoy		-5.0 %	145.3 %	14.9 %	28.5 %	9.8 %	6.4 %	9.6 %
Sales	8.6 %	51.6	60.3	142.7	186.6	205.0	218.2	239.1
Change Sales yoy		211.5 %	16.9 %	136.6 %	30.8 %	9.8 %	6.4 %	9.6 %
EBITDA (pro forma)	21.0 %	12.3	48.2	50.0	62.2	66.4	73.7	110.3
Margin (pro forma)		23.8 %	38.1 %	34.4 %	33.3 %	32.4 %	33.8 %	46.1 %
EBITDA	23.2 %	8.3	0.4	46.7	57.9	61.6	71.7	108.3
Margin		16.2 %	0.7 %	32.7 %	31.0 %	30.0 %	32.8 %	45.3 %
EBIT	31.0 %	-1.0	-9.3	29.3	37.6	37.8	48.5	84.6
Margin		-2.0 %	-15.4 %	20.5 %	20.2 %	18.4 %	22.2 %	35.4 %
Net income	-	-6.8	-15.9	49.0	-3.3	-18.0	5.1	20.0
EPS	-	-0.81	-1.52	4.48	-0.31	-1.72	0.49	1.92
FCFPS		0.57	-0.71	2.90	2.74	-0.76	2.23	4.48
FCF / Market cap		1.8 %	-2.9 %	15.4 %	12.5 %	-5.2 %	15.1 %	30.4 %
EV / Sales		3.6 x	6.0 x	1.6 x	1.6 x	1.7 x	1.5 x	1.2 x
EV / EBITDA		22.4 x	859.3 x	5.0 x	5.0 x	5.8 x	4.7 x	2.7 x
EV / EBIT		n.a.	n.a.	8.0 x	7.7 x	9.5 x	7.0 x	3.5 x
P / E		n.a.	n.a.	4.2 x	n.a.	n.a.	30.1 x	7.7 x
FCF Potential Yield		2.8 %	-1.1 %	35.5 %	15.6 %	12.5 %	17.7 %	28.9 %
Net Debt		-69.3	110.6	28.1	49.3	59.6	39.3	-3.7
ROCE (NOPAT)		n.a.	n.a.	4.5 %	5.5 %	n.a.	10.2 %	17.7 %
Guidance:		growth at high margins						

Sales (pro forma) development
in EUR m




Source: Warburg Research

Sales by regions
2023; in %



Source: Warburg Research

adj. EBITDA (pro forma) development
in EUR m



Source: Warburg Research


Company Background

- Founded in 2017 by CEO Marco Brockhaus and other team members as the successor to three private equity funds.
- In contrast to the limited lifetime of a PE fund, the structure of a holding company precludes forced exits and management influence is increased.
- IPO in 2020
- Portfolio companies are managed by a lean holding with around 10 employees

Competitive Quality


- Brockhaus has an extensive network and over 20 years of expertise in PE transactions to support portfolio companies to grow and expand into new markets
- Focus of investment is scalable B2B business models in high-tech German Mittelstand companies that generate high margins and superior cash returns
- Typically, the companies invested in are not large enough to go to the capital market alone but are champions in their niches
- Brockhaus' investments represent a niche that asset managers have little or no access to.

adj. EBIT development
in EUR m




Source: Warburg Research

Sales by segments
2023; in %



Source: Warburg Research

Net income development
in EUR m



Source: Warburg Research

Sum of the parts

(EURm)	2025	WACC -1%	WACC +1%
Equity value IHSE (DCF)	58	73	46
Share Brockhaus	100%	100%	100%
	58	73	46
Equity value Bikeleasing (DCF)	1,105	1,155	1,059
Share Brockhaus	52%	52%	52%
	577	604	554
FY 24e adj. EBITDA Holding	-6	-6	-6
Discount factor	6%	5%	7%
Value holding	-114	-139	-96
Sum of the Parts	521	537	504
Less net debt (-cash) holding	1	1	1
Equity value Brockhaus Technologies	520	536	503
Number of shares	10.45	10.45	10.45
Value per share	49.78	51.30	48.11

- IHSE and Bikeleasing valued by separate DCF models
- Debt at portfolio company level is included in DCF model. Remaining debt at holding level is subtracted separately.
- Holding cost are discounted in a single stage model with same WACC as portfolio companies.
- Holding cost are expected to be subject to inflation of 4.5% p.a. subtracted from the discount rate.
- Deal generating capability of holding is a hidden reserve and not valued currently

Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	1.1 x	1.1 x	0.8 x	0.9 x	0.7 x	0.7 x	0.6 x
Book value per share ex intangibles	6.81	-16.15	-7.70	-9.41	-9.76	-7.35	-4.14
EV / Sales	3.6 x	6.0 x	1.6 x	1.6 x	1.7 x	1.5 x	1.2 x
EV / EBITDA	22.4 x	859.3 x	5.0 x	5.0 x	5.8 x	4.7 x	2.7 x
EV / EBIT	n.a.	n.a.	8.0 x	7.7 x	9.5 x	7.0 x	3.5 x
EV / EBIT adj.*	17.6 x	18.3 x	5.0 x	5.0 x	5.9 x	5.0 x	2.8 x
P / FCF	54.1 x	n.a.	6.5 x	8.0 x	n.a.	6.6 x	3.3 x
P / E	n.a.	n.a.	4.2 x	n.a.	n.a.	30.1 x	7.7 x
P / E adj.*	57.9 x	52.2 x	25.9 x	19.5 x	27.3 x	6.8 x	4.1 x
Dividend Yield	n.a.	n.a.	n.a.	1.0 %	1.9 %	2.5 %	3.3 %
FCF Potential Yield (on market EV)	2.8 %	-1.1 %	35.5 %	15.6 %	12.5 %	17.7 %	28.9 %

*Adjustments made for: -

Company Specific Items							
	2020	2021	2022	2023	2024e	2025e	2026e
Sales (pro forma)	51.6	126.5	145.3	186.7	205.0	218.2	239.1
yoy	-5.0 %	145.3 %	14.9 %	28.5 %	9.8 %	6.4 %	9.6 %
EBITDA (pro forma)	12.3	48.2	50.0	62.2	66.4	73.7	110.3
Margin (pro forma)	23.8 %	38.1 %	34.4 %	33.3 %	32.4 %	33.8 %	46.1 %

Consolidated profit & loss

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Sales	51.6	60.3	142.7	186.6	205.0	218.2	239.1
Change Sales yoy	211.5 %	16.9 %	136.6 %	30.8 %	9.8 %	6.4 %	9.6 %
Increase / decrease in inventory	-0.1	-0.2	-0.2	0.1	0.0	0.0	0.0
Own work capitalised	0.9	1.4	1.0	1.0	0.0	0.0	0.0
Total Sales	52.3	61.5	143.5	187.7	205.0	218.2	239.1
Material expenses	13.8	14.2	51.7	69.3	75.9	80.7	88.5
Gross profit	38.6	47.3	91.7	118.4	129.2	137.4	150.6
<i>Gross profit margin</i>	<i>74.7 %</i>	<i>78.4 %</i>	<i>64.3 %</i>	<i>63.4 %</i>	<i>63.0 %</i>	<i>63.0 %</i>	<i>63.0 %</i>
Personnel expenses	19.5	21.8	26.6	33.1	39.0	41.4	45.4
Other operating income	1.5	2.0	1.5	4.1	2.1	2.2	2.4
Other operating expenses	12.0	26.9	19.5	31.5	30.7	26.5	-0.7
Unfrequent items	-0.1	-0.2	-0.3	0.0	0.0	0.0	0.0
EBITDA	8.3	0.4	46.7	57.9	61.6	71.7	108.3
<i>Margin</i>	<i>16.2 %</i>	<i>0.7 %</i>	<i>32.7 %</i>	<i>31.0 %</i>	<i>30.0 %</i>	<i>32.8 %</i>	<i>45.3 %</i>
Depreciation of fixed assets	1.7	2.1	3.2	4.6	3.7	3.9	4.3
EBITA	6.7	-1.7	43.5	53.3	57.9	67.7	104.0
Amortisation of intangible assets	7.7	7.6	14.2	15.7	20.1	19.2	19.4
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	-1.0	-9.3	29.3	37.6	37.8	48.5	84.6
<i>Margin</i>	<i>-2.0 %</i>	<i>-15.4 %</i>	<i>20.5 %</i>	<i>20.2 %</i>	<i>18.4 %</i>	<i>22.2 %</i>	<i>35.4 %</i>
EBIT adj.	10.6	19.7	46.8	57.7	60.7	68.0	104.1
Interest income	0.1	0.0	4.8	0.5	1.2	1.2	1.2
Interest expenses	3.9	6.2	14.7	19.8	15.8	14.6	14.3
Other financial income (loss)	0.0	0.0	0.0	0.0	4.9	-3.0	-3.0
EBT	-4.8	-15.4	19.3	18.4	12.3	32.1	68.5
<i>Margin</i>	<i>-9.4 %</i>	<i>-25.5 %</i>	<i>13.5 %</i>	<i>9.9 %</i>	<i>6.0 %</i>	<i>14.7 %</i>	<i>28.7 %</i>
Total taxes	1.9	3.4	8.9	9.1	15.0	9.3	19.9
Net income from continuing operations	-6.8	-18.8	10.5	9.3	-2.7	22.8	48.6
Income from discontinued operations (net of tax)	0.0	0.0	48.0	0.0	0.0	0.0	0.0
Net income before minorities	-6.8	-18.8	58.5	9.3	-2.7	22.8	48.6
Minority interest	0.0	-2.9	9.4	12.7	15.3	17.7	28.6
Net income	-6.8	-15.9	49.0	-3.3	-18.0	5.1	20.0
<i>Margin</i>	<i>-13.1 %</i>	<i>-26.3 %</i>	<i>34.3 %</i>	<i>-1.8 %</i>	<i>-8.8 %</i>	<i>2.4 %</i>	<i>8.4 %</i>
Number of shares, average	8.3	10.4	10.9	10.9	10.4	10.4	10.4
EPS	-0.81	-1.52	4.48	-0.31	-1.72	0.49	1.92
EPS adj.	0.53	0.46	0.73	1.13	0.54	2.18	3.60

*Adjustments made for:


Guidance: growth at high margins

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	85.0 %	101.0 %	67.6 %	69.6 %	70.0 %	67.2 %	54.7 %
Operating Leverage	-0.3 x	46.5 x	n.a.	0.9 x	0.0 x	4.4 x	7.8 x
EBITDA / Interest expenses	2.1 x	0.1 x	3.2 x	2.9 x	3.9 x	4.9 x	7.6 x
Tax rate (EBT)	-39.7 %	-22.0 %	45.8 %	49.4 %	121.9 %	29.0 %	29.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	25.9 %	n.m.	17.0 %	10.4 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Sales, EBITDA


in EUR m



Source: Warburg Research


Operating Performance

in %



Source: Warburg Research

Performance per Share



Source: Warburg Research


Consolidated balance sheet

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Assets							
Goodwill and other intangible assets	152.7	398.9	356.9	356.6	324.1	304.9	285.5
thereof other intangible assets	53.7	147.7	133.5	119.3	99.1	79.9	60.5
thereof Goodwill	91.4	243.6	221.9	222.8	222.8	222.8	222.8
Property, plant and equipment	11.7	16.2	7.6	12.9	11.5	11.3	11.5
Financial assets	0.0	0.0	0.0	0.0	-7.9	-7.9	-7.9
Other long-term assets	0.6	82.7	131.4	139.5	175.1	196.8	206.8
Fixed assets	165.0	497.7	496.0	509.0	502.8	505.1	495.9
Inventories	9.7	12.6	10.9	17.7	15.8	16.8	18.4
Accounts receivable	7.2	20.2	29.4	36.2	61.9	65.9	72.2
Liquid assets	123.5	30.3	70.8	53.7	18.4	13.7	31.7
Other short-term assets	0.9	53.7	48.4	49.6	49.0	44.7	39.0
Current assets	141.4	116.8	159.5	157.2	145.1	141.1	161.3
Total Assets	306.4	614.5	655.5	666.2	648.0	646.2	657.2
Liabilities and shareholders' equity							
Subscribed capital	10.4	10.4	10.9	10.9	10.9	10.9	10.9
Capital reserve	227.7	227.7	240.1	240.1	240.1	240.1	240.1
Retained earnings	0.0	0.0	0.0	18.3	-2.0	0.1	16.3
Other equity components	-14.6	-16.0	21.6	-11.0	-26.9	-23.1	-25.1
Shareholders' equity	223.4	222.0	272.7	258.3	222.1	228.1	242.2
Minority interest	0.0	32.9	42.6	39.5	54.8	72.5	101.1
Total equity	223.4	254.9	315.3	297.8	276.9	300.6	343.3
Provisions	2.2	4.9	0.2	0.2	0.2	0.2	0.2
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	54.3	140.9	98.9	103.0	78.0	53.0	28.0
Short-term financial liabilities	6.1	17.0	5.3	15.9	15.9	15.9	15.9
Accounts payable	2.5	12.7	15.5	15.2	25.9	27.6	30.2
Other liabilities	24.0	201.0	225.7	250.0	267.0	264.8	255.5
Liabilities	83.0	359.6	340.2	368.3	371.1	345.6	313.9
Total liabilities and shareholders' equity	306.4	614.5	655.5	666.2	648.0	646.2	657.2


Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	2.0 x	1.7 x	4.4 x	3.6 x	3.2 x	3.3 x	3.3 x
Capital Employed Turnover	0.3 x	0.2 x	0.4 x	0.5 x	0.6 x	0.6 x	0.7 x
ROA	-4.1 %	-3.2 %	9.9 %	-0.7 %	-3.6 %	1.0 %	4.0 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	4.5 %	5.5 %	n.a.	10.2 %	17.7 %
ROE	-3.9 %	-7.1 %	19.8 %	-1.3 %	-7.5 %	2.3 %	8.5 %
Adj. ROE	2.6 %	2.1 %	3.3 %	4.6 %	2.4 %	10.1 %	16.0 %
Balance sheet quality							
Net Debt	-69.3	110.6	28.1	49.3	59.6	39.3	-3.7
Net Financial Debt	-69.3	110.6	28.1	49.3	59.6	39.3	-3.7
Net Gearing	-31.0 %	43.4 %	8.9 %	16.6 %	21.5 %	13.1 %	-1.1 %
Net Fin. Debt / EBITDA	n.a.	n.a.	60.1 %	85.2 %	96.7 %	54.8 %	n.a.
Book Value / Share	21.5	20.3	24.9	24.7	21.3	21.8	23.2
Book value per share ex intangibles	6.8	-16.2	-7.7	-9.4	-9.8	-7.4	-4.1


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net income	-6.8	-18.8	58.5	9.3	-2.7	22.8	48.6
Depreciation of fixed assets	9.4	9.7	5.9	4.6	3.7	3.9	4.3
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	7.7	7.6	14.2	15.7	20.1	19.2	19.4
Increase/decrease in long-term provisions	0.0	-0.1	0.0	0.0	0.0	0.0	0.0
Other non-cash income and expenses	-3.4	-9.9	-31.9	20.3	-15.0	-17.0	-17.0
Cash Flow before NWC change	7.0	-11.5	46.6	49.9	6.1	29.0	55.4
Increase / decrease in inventory	-1.1	-2.3	-16.1	-6.8	1.9	-1.0	-1.6
Increase / decrease in accounts receivable	0.0	0.0	0.0	-6.8	-25.7	-4.0	-6.3
Increase / decrease in accounts payable	-0.2	7.6	4.6	-0.3	10.7	1.7	2.6
Increase / decrease in other working capital positions	0.0	0.0	-0.2	-1.2	1.3	1.3	1.3
Increase / decrease in working capital (total)	-1.3	5.3	-11.7	-15.1	-11.7	-2.0	-4.0
Net cash provided by operating activities [1]	5.7	-6.2	34.9	34.8	-5.6	27.0	51.4
Investments in intangible assets	-0.1	0.0	0.0	0.0	0.0	0.0	0.0
Investments in property, plant and equipment	-1.0	-1.2	-1.3	-2.1	-2.3	-3.7	-4.5
Payments for acquisitions	-0.1	-142.1	0.0	-15.2	0.0	0.0	0.0
Financial investments	-0.4	-0.8	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.1	56.2	10.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-1.4	-144.0	53.0	-9.9	-2.3	-3.7	-4.5
Change in financial liabilities	0.0	58.0	-42.4	-15.8	-25.0	-25.0	-25.0
Dividends paid	0.0	0.0	0.0	0.0	-2.3	-3.0	-3.9
Purchase of own shares	0.0	0.0	0.0	-11.0	0.0	0.0	0.0
Capital measures	112.7	0.0	0.0	0.0	0.0	0.0	0.0
Other	-10.4	-2.4	-4.3	-15.8	0.0	0.0	0.0
Net cash provided by financing activities [3]	102.3	55.7	-46.7	-42.6	-27.3	-28.0	-28.9
Change in liquid funds [1]+[2]+[3]	106.6	-94.5	41.2	-17.7	-35.2	-4.7	17.9
Effects of exchange-rate changes on cash	0.2	0.3	0.2	-0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	124.0	29.3	71.8	53.0	18.4	13.7	31.7

Financial Ratios


	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	4.7	-7.4	31.8	30.0	-7.9	23.3	46.8
Free Cash Flow / Sales	9.2 %	-12.2 %	22.3 %	16.1 %	-3.9 %	10.7 %	19.6 %
Free Cash Flow Potential	5.3	-3.8	83.5	45.2	44.8	59.6	85.0
Free Cash Flow / Net Profit	-70.0 %	46.5 %	64.8 %	-897.5 %	44.1 %	453.5 %	233.7 %
Interest Received / Avg. Cash	0.1 %	0.1 %	9.5 %	0.8 %	3.3 %	7.5 %	5.3 %
Interest Paid / Avg. Debt	6.7 %	6.3 %	12.3 %	19.6 %	17.4 %	22.2 %	35.2 %
Management of Funds							
Investment ratio	2.0 %	1.9 %	0.9 %	1.1 %	1.1 %	1.7 %	1.9 %
Maint. Capex / Sales	2.1 %	1.5 %	1.7 %	1.9 %	0.9 %	1.3 %	1.4 %
Capex / Dep	11.2 %	12.1 %	7.2 %	10.1 %	9.8 %	16.0 %	19.1 %
Avg. Working Capital / Sales	27.0 %	28.5 %	15.7 %	17.0 %	22.1 %	24.5 %	24.2 %
Trade Debtors / Trade Creditors	284.5 %	158.4 %	190.1 %	238.9 %	239.0 %	238.8 %	239.1 %
Inventory Turnover	1.4 x	1.1 x	4.7 x	3.9 x	4.8 x	4.8 x	4.8 x
Receivables collection period (days)	51	122	75	71	110	110	110
Payables payment period (days)	67	326	109	80	125	125	125
Cash conversion cycle (Days)	241	118	43	84	62	61	62

CAPEX and Cash Flow


in EUR m



Free Cash Flow Generation



Working Capital



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Brockhaus Technologies	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A2GSU42.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	143	71
Hold	48	24
Sell	6	3
Rating suspended	5	2
Total	202	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	37	73
Hold	10	20
Sell	1	2
Rating suspended	3	6
Total	51	100

PRICE AND RATING HISTORY BROCKHAUS TECHNOLOGIES AS OF 26.06.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemier +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Fabio Hölscher +49 40 309537-240
Automobiles, Car Suppliers fhoelscher@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate, Construction pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Hannes Müller +49 40 309537-255
Software, IT hmueller@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate, Telco sstippig@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Klaus Schilling +49 69 5050-7400
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom, Ireland mfritsch@mmwarburg.com

Rudolf Alexander Michaelis +49 40 3282-2649
Germany rmichaelis@mmwarburg.com

Roman Alexander Niklas +49 69 5050-7412
Switzerland, Poland, Italy rniklas@mmwarburg.com

Sascha Propp +49 40 3282-2656
France spropp@mmwarburg.com

Leyan Ilkbahar +49 40 3282-2695
Roadshow/Marketing liikbahar@mmwarburg.com

Antonia Möller +49 69 5050-7417
Roadshow/Marketing amoeller@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Christian Salomon +49 40 3282-2685
Sales Trading csalomon@mmwarburg.com

DESIGNATED SPONSORING

Sebastian Schulz +49 40 3282-2631
Designated Sponsoring sschulz@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Designated Sponsoring jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

LSEG www.lseg.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com